Literature DB >> 25541633

The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes.

Siri Fredheim1, Marie-Louise M Andersen, Sven Pörksen, Lotte B Nielsen, Christian Pipper, Lars Hansen, Jens J Holst, Jane Thomsen, Jesper Johannesen, Henrik B Mortensen, Jannet Svensson.   

Abstract

AIMS/HYPOTHESIS: The influence of glucagon on glycaemic control in type 1 diabetes is debated. We investigated the relationship between postprandial glucagon levels and HbA1c during a period up to 60 months after diagnosis of childhood type 1 diabetes.
METHODS: The Danish remission phase cohort comprised 129 children (66 boys) with type 1 diabetes whose mean (SD) age at onset was 10.0 (3.9) years. Liquid mixed-meal tests were performed prospectively at 1, 3, 6 and 12 months and a subset of 40 patients completed follow-up at 60 months. Postprandial (90 min) plasma levels of glucagon, glucose (PG), C-peptide, total glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and HbA1c were analysed. Multivariate regression (repeated measurements with all five visits included) was applied and results expressed as relative change (95% CI).
RESULTS: Postprandial glucagon levels increased 160% from 1 to 60 months after diagnosis (p < 0.0001). A doubling in postprandial PG corresponded to a 21% increase in postprandial glucagon levels (p = 0.0079), whereas a doubling in total GLP-1 levels corresponded to a 33% increase in glucagon levels (p < 0.0001). Postprandial glucagon associated negatively with postprandial C-peptide (p = 0.017). A doubling in postprandial glucagon corresponded to a 3% relative increase in HbA1c levels (p = 0.0045). CONCLUSIONS/
INTERPRETATION: Postprandial glucagon levels were associated with deterioration of glycaemic control and declining beta cell function in the first 5 years after diagnosis of type 1 diabetes. The positive association of glucagon with total GLP-1 and PG suggests that physiological regulation of alpha cell secretion in type 1 diabetes is seriously disturbed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25541633     DOI: 10.1007/s00125-014-3486-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  38 in total

1.  Partial remission definition: validation based on the insulin dose-adjusted HbA1c (IDAA1C) in 129 Danish children with new-onset type 1 diabetes.

Authors:  Marie Louise C Max Andersen; Philip Hougaard; Sven Pörksen; Lotte B Nielsen; Siri Fredheim; Jannet Svensson; Jane Thomsen; Jennifer Vikre-Jørgensen; Thomas Hertel; Jacob S Petersen; Lars Hansen; Henrik B Mortensen
Journal:  Pediatr Diabetes       Date:  2014-11       Impact factor: 4.866

2.  Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.

Authors:  S L Ellis; E G Moser; J K Snell-Bergeon; A S Rodionova; R M Hazenfield; S K Garg
Journal:  Diabet Med       Date:  2011-10       Impact factor: 4.359

3.  Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients.

Authors:  Urd Kielgast; Meena Asmar; Sten Madsbad; Jens J Holst
Journal:  J Clin Endocrinol Metab       Date:  2010-03-05       Impact factor: 5.958

4.  Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas.

Authors:  J de Heer; C Rasmussen; D H Coy; J J Holst
Journal:  Diabetologia       Date:  2008-09-16       Impact factor: 10.122

Review 5.  Brain glucose sensing, counterregulation, and energy homeostasis.

Authors:  Nell Marty; Michel Dallaporta; Bernard Thorens
Journal:  Physiology (Bethesda)       Date:  2007-08

6.  Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.

Authors:  Kirsten Vollmer; Jens J Holst; Birgit Baller; Mark Ellrichmann; Michael A Nauck; Wolfgang E Schmidt; Juris J Meier
Journal:  Diabetes       Date:  2007-12-05       Impact factor: 9.461

7.  Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.

Authors:  Urd Kielgast; Thure Krarup; Jens Juul Holst; Sten Madsbad
Journal:  Diabetes Care       Date:  2011-05-18       Impact factor: 19.112

8.  Control of insulin secretion by cholinergic signaling in the human pancreatic islet.

Authors:  Judith Molina; Rayner Rodriguez-Diaz; Alberto Fachado; M Caroline Jacques-Silva; Per-Olof Berggren; Alejandro Caicedo
Journal:  Diabetes       Date:  2014-03-21       Impact factor: 9.461

9.  Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes.

Authors:  Rachel E J Besser; Beverley M Shields; Rosaura Casas; Andrew T Hattersley; Johnny Ludvigsson
Journal:  Diabetes Care       Date:  2012-10-30       Impact factor: 19.112

10.  Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes.

Authors:  Rebecca J Brown; Ninet Sinaii; Kristina I Rother
Journal:  Diabetes Care       Date:  2008-07       Impact factor: 19.112

View more
  11 in total

1.  Circulating microRNA levels predict residual beta cell function and glycaemic control in children with type 1 diabetes mellitus.

Authors:  Nasim Samandari; Aashiq H Mirza; Lotte B Nielsen; Simranjeet Kaur; Philip Hougaard; Siri Fredheim; Henrik B Mortensen; Flemming Pociot
Journal:  Diabetologia       Date:  2016-11-19       Impact factor: 10.122

2.  Effect of Afrezza on Glucose Dynamics During HCL Treatment.

Authors:  Alfonso Galderisi; Nathan Cohen; Peter Calhoun; Kristen Kraemer; Marc Breton; Stuart Weinzimer; Eda Cengiz
Journal:  Diabetes Care       Date:  2020-07-13       Impact factor: 19.112

3.  Associations of serum glucagon levels with glycemic variability in type 1 diabetes with different disease durations.

Authors:  Ke Li; Wen-Jing Song; Xia Wu; Dan-Yang Gu; Pu Zang; Ping Gu; Bin Lu; Jia-Qing Shao
Journal:  Endocrine       Date:  2018-06-18       Impact factor: 3.633

4.  Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.

Authors:  Alfonso Galderisi; Jennifer Sherr; Michelle VanName; Lori Carria; Melinda Zgorski; Eileen Tichy; Kate Weyman; Eda Cengiz; Stuart Weinzimer; William Tamborlane
Journal:  J Clin Endocrinol Metab       Date:  2018-03-01       Impact factor: 5.958

5.  Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial.

Authors:  Jeniece Trast Ilkowitz; Ranjitha Katikaneni; Martin Cantwell; Neesha Ramchandani; Rubina A Heptulla
Journal:  J Diabetes Sci Technol       Date:  2016-08-22

6.  Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes.

Authors:  Maritza J Romero; Rudolf Lucas; Huijuan Dou; Supriya Sridhar; Istvan Czikora; Eby M Mosieri; Ferenc G Rick; Norman L Block; Subbaramiah Sridhar; David Fulton; Neal L Weintraub; Zsolt Bagi; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-01       Impact factor: 11.205

Review 7.  Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions.

Authors:  Marco Infante; David A Baidal; Michael R Rickels; Andrea Fabbri; Jay S Skyler; Rodolfo Alejandro; Camillo Ricordi
Journal:  Artif Organs       Date:  2021-07-15       Impact factor: 2.663

8.  Decreased α-cell mass and early structural alterations of the exocrine pancreas in patients with type 1 diabetes: An analysis based on the nPOD repository.

Authors:  Fidéline Bonnet-Serrano; Marc Diedisheim; Roberto Mallone; Etienne Larger
Journal:  PLoS One       Date:  2018-01-19       Impact factor: 3.240

9.  Abnormal regulation of glucagon secretion by human islet alpha cells in the absence of beta cells.

Authors:  Wei Liu; Tatsuya Kin; Siuhong Ho; Craig Dorrell; Sean R Campbell; Ping Luo; Xiaojuan Chen
Journal:  EBioMedicine       Date:  2019-11-26       Impact factor: 11.205

10.  Impact of glucagon response on early postprandial glucose excursions irrespective of residual β-cell function in type 1 diabetes: A cross-sectional study using a mixed meal tolerance test.

Authors:  Ayako Ito; Ichiro Horie; Masaki Miwa; Ayaka Sako; Tetsuro Niri; Yomi Nakashima; Riyoko Shigeno; Ai Haraguchi; Shoko Natsuda; Satoru Akazawa; Akie Kamada; Atsushi Kawakami; Norio Abiru
Journal:  J Diabetes Investig       Date:  2021-01-22       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.